James O Armitage Center for Hematological Malignancies Research

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Non-Hodgkin's Lymphoma Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Profiles

No photo of James Olen Armitage

James Olen Armitage, MD

Person: Member, Academic, Clinician

19752018

Research Output 1974 2019

Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid

Ryan, E. M., Duryee, M. J., Hollins, A., Dover, S. K., Pirruccello, S. J., Sayles, H., Real, K. D., Hunter, C. D., Thiele, G. M. & Mikuls, T. R., Feb 5 2019, In : Journal of Pharmaceutical and Biomedical Analysis. 164, p. 460-466 7 p.

Research output: Contribution to journalArticle

Urate Oxidase
Uric Acid
Citric Acid
Antioxidants
Hydrogen Peroxide

Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

Holstein, S. A., Suman, V. J. & McCarthy, P. L., Jan 1 2019, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalArticle

Autografts
Standard of Care
Multiple Myeloma
lenalidomide

Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Kothari, S., Hillengass, J., McCarthy, P. L. & Holstein, S. A., Jan 1 2019, (Accepted/In press) In : Current Hematologic Malignancy Reports.

Research output: Contribution to journalArticle

Residual Neoplasm
Multiple Myeloma
Clinical Trials
Disease-Free Survival
Biomarkers